CN111978236A - Preparation method of N-substituted-3-morpholinyl-4-phenylseleno maleimide compound - Google Patents
Preparation method of N-substituted-3-morpholinyl-4-phenylseleno maleimide compound Download PDFInfo
- Publication number
- CN111978236A CN111978236A CN202010816745.0A CN202010816745A CN111978236A CN 111978236 A CN111978236 A CN 111978236A CN 202010816745 A CN202010816745 A CN 202010816745A CN 111978236 A CN111978236 A CN 111978236A
- Authority
- CN
- China
- Prior art keywords
- substituted
- reaction
- morpholinyl
- maleimide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 maleimide compound Chemical class 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims abstract description 30
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract description 26
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003446 ligand Substances 0.000 claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052802 copper Inorganic materials 0.000 claims abstract description 10
- 239000010949 copper Substances 0.000 claims abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 239000001301 oxygen Substances 0.000 claims abstract description 10
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 10
- 150000003624 transition metals Chemical class 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 13
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 13
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 13
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical group I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 13
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical group C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 claims description 12
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 12
- 229910001958 silver carbonate Inorganic materials 0.000 claims description 12
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 claims description 12
- 239000002585 base Substances 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004896 high resolution mass spectrometry Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- AILGRWSIRAPLCJ-UHFFFAOYSA-N 3-[4-(3-methylbut-2-enoxy)phenyl]-4-(2-methylpropyl)pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(CC(C)C)=C1C1=CC=C(OCC=C(C)C)C=C1 AILGRWSIRAPLCJ-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 229940045803 cuprous chloride Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229940042040 innovative drug Drugs 0.000 description 2
- WXUJAQBSBZLVEV-UHFFFAOYSA-N isogranulatimide Chemical compound N1C2=CC=CC=C2C2=C1N1C=NC=C1C1=C2C(=O)NC1=O WXUJAQBSBZLVEV-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 2
- 229940071536 silver acetate Drugs 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical class O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 description 1
- KTGNEWWMWGBEQP-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]pyrrole-2,5-dione Chemical compound C1=CC(F)=CC=C1CN1C(=O)C=CC1=O KTGNEWWMWGBEQP-UHFFFAOYSA-N 0.000 description 1
- PKRXXDLNTFLPRG-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]pyrrole-2,5-dione Chemical compound C1=CC(C)=CC=C1CN1C(=O)C=CC1=O PKRXXDLNTFLPRG-UHFFFAOYSA-N 0.000 description 1
- HLZMYWLMBBLASX-UHFFFAOYSA-N 1-benzyl-3-(4-methoxyphenylamino)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 HLZMYWLMBBLASX-UHFFFAOYSA-N 0.000 description 1
- MKRBAPNEJMFMHU-UHFFFAOYSA-N 1-benzylpyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CC1=CC=CC=C1 MKRBAPNEJMFMHU-UHFFFAOYSA-N 0.000 description 1
- BQTPKSBXMONSJI-UHFFFAOYSA-N 1-cyclohexylpyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1CCCCC1 BQTPKSBXMONSJI-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- LSXYUYXMNIJERR-UHFFFAOYSA-N C1=C([N+]([O-])=O)C(O)=CC=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O LSXYUYXMNIJERR-UHFFFAOYSA-N 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 229940122761 Liver X receptor agonist Drugs 0.000 description 1
- 229940124148 Macrophage inhibitor Drugs 0.000 description 1
- 229940123882 Porcupine inhibitor Drugs 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- NUMFSYMJEOVXJE-UHFFFAOYSA-L copper difluoromethanesulfonate Chemical compound FC(S(=O)(=O)[O-])F.[Cu+2].FC(S(=O)(=O)[O-])F NUMFSYMJEOVXJE-UHFFFAOYSA-L 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000766 liver X receptor agonist Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000005887 phenylation reaction Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005922 selenation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrrole Compounds (AREA)
Abstract
本发明涉及一种N‑取代‑3‑吗啉基‑4‑苯硒基马来酰亚胺化合物的制备方法,在有机溶剂中,氧气条件下,以苯硼酸、硒粉、吗啡啉和N‑取代马来酰亚胺为反应原料,在过渡金属铜催化剂、银盐、配体和碱的共同协同催化作用下,通过四组分串联反应得到N‑取代‑3‑吗啉基‑4‑苯硒基马来酰亚胺化合物。所述方法反应条件简单、产物的产率和纯度高,为N‑取代‑3‑吗啉基‑4‑苯硒基马来酰亚胺化合物的制备开拓了合成路线和方法,具有良好的应用潜力和研究价值。The invention relates to a preparation method of an N-substituted-3-morpholinyl-4-phenylselenoyl maleimide compound. In an organic solvent, under oxygen conditions, phenylboronic acid, selenium powder, morpholine and N ‑Substituted maleimide is used as the raw material for the reaction, and under the joint catalysis of transition metal copper catalyst, silver salt, ligand and base, N‑substituted‑3‑morpholinyl‑4‑ is obtained through a four-component series reaction Phenylselenomaleimide compound. The method has simple reaction conditions, high product yield and high purity, opens up a synthetic route and method for the preparation of N-substituted-3-morpholinyl-4-phenylselenylmaleimide compounds, and has good application potential and research value.
Description
技术领域technical field
本发明属于有机化合物合成技术领域,尤其是涉及一种N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备方法。The invention belongs to the technical field of organic compound synthesis, in particular to a preparation method of an N-substituted-3-morpholinyl-4-phenylselenyl maleimide compound.
背景技术Background technique
3,4-双官能化马来酰亚胺作为核心骨架广泛存在于海洋天然生物碱和具有重要生物活性的抗肿瘤活性分子、候选药物分子和AIE荧光材料中,例如:G2细胞周期检查点激酶Isogranulatimide、LPS诱导巨噬细胞抑制剂Himanimide A、抗乳腺癌药Camphorataimide B、特异性Porcupine抑制剂、海洋生物碱aqabamycin G和肝脏x受体激动剂GSK3987。此外,马来酰亚胺还可以进行丰富多样的官能团转换合成琥珀酰亚胺、四氢吡咯和2-吡咯酮等衍生物。因此,探索从廉价易得的原料高效构建3,4-双官能化马来酰亚胺成为当前有机化学、药物化学和材料科学研究的热点之一。3,4-Difunctionalized maleimide as the core skeleton widely exists in marine natural alkaloids and antitumor active molecules with important biological activities, drug candidate molecules and AIE fluorescent materials, such as: G2 cell cycle checkpoint kinase Isogranulatimide, LPS-induced macrophage inhibitor Himanimide A, anti-breast cancer drug Camphorataimide B, specific Porcupine inhibitor, marine alkaloid aqabamycin G and liver X receptor agonist GSK3987. In addition, maleimide can also be converted into various functional groups to synthesize derivatives such as succinimide, tetrahydropyrrole and 2-pyrrolidone. Therefore, exploring the efficient construction of 3,4-difunctionalized maleimides from cheap and readily available raw materials has become one of the hotspots in current organic chemistry, medicinal chemistry and materials science.
3,4-双官能化马来酰亚胺的活性分子Reactive molecules of 3,4-difunctionalized maleimides
另外一方面,考虑到芳硒醚化合物在药物研发中具有潜在的应用价值,发展将芳硒基引入马来酰亚胺分子结构中的方法引起了合成化学家们的关注。Baidya课题组报道了过渡金属钌催化马来酰亚胺与二芳基二硒醚的氧化硒基化反应,然而,二芳基二硒醚的预先制备和贵金属钌催化剂的使用,使得该反应不能够有效地应用于药物分子的后期修饰,减少了创新药物分子的发现机会。因此,发展新型的硒基化试剂,对马来酰亚胺直接催化胺芳硒基化将是一种有效的策略,一步反应即可实现碳-氮键和双碳-硒键的高效构建和含药物分子的引入。最近,我们课题组报道了铜催化马来酰亚胺的胺硒基化反应(OxidativeAminoarylselenation of Maleimides via Copper-Catalyzed Four-Component Cross-Coupling,Organic Letters 2019,21,3,745-748)。考虑到芳硒基和马来酰亚胺母核结构在创新药物研发的重要性,因此,对于简便、易于处理、底物廉价易得的原料来制备N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物显得尤为重要,尤其是利用廉价易得、稳定、实验操作方便的苯硼酸作为苯基化试剂制备N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的反应,至今未曾报道,仍存在继续进行研究和探索的必要,这也是本发明得以完成的基础和动力所在。On the other hand, considering the potential application value of arylselenide compounds in drug research and development, the development of methods to introduce arylselenoyl groups into the molecular structure of maleimide has attracted the attention of synthetic chemists. Baidya's group reported that transition metal ruthenium catalyzed the oxidoselenylation of maleimide and diaryl diselenide. However, the pre-preparation of diaryl diselenide and the use of precious metal ruthenium catalyst made this reaction impossible. It can be effectively applied to late-stage modification of drug molecules, reducing the chance of discovery of innovative drug molecules. Therefore, the development of new selenylation reagents to directly catalyze amine arylselenylation of maleimide will be an effective strategy, which can realize the efficient construction of carbon-nitrogen bonds and double carbon-selenium bonds in one step. Introduction of drug-containing molecules. Recently, our research group reported the copper-catalyzed amine selenation of maleimides (Oxidative Aminoarylselenation of Maleimides via Copper-Catalyzed Four-Component Cross-Coupling, Organic Letters 2019, 21, 3, 745-748). Considering the importance of arylselenyl and maleimide core structures in the development of innovative drugs, it is necessary to prepare N-substituted-3-morpholinyl-4 from facile, easy-to-handle, inexpensive and readily available starting materials. -Phenylselenylmaleimide compounds are particularly important, especially the preparation of N-substituted-3-morpholinyl-4-phenylselenyl by using phenylboronic acid, which is cheap, easy to obtain, stable, and convenient for experimental operation as a phenylation reagent The reaction of the maleimide compound has not been reported so far, and there is still a need for continued research and exploration, which is also the basis and motivation for the completion of the present invention.
发明内容SUMMARY OF THE INVENTION
本发明所要解决的技术问题是N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备方法的合成路线问题。The technical problem to be solved by the present invention is the synthetic route problem of the preparation method of the N-substituted-3-morpholinyl-4-phenylselenyl maleimide compound.
为解决以上技术问题,本发明提供下述技术方案:For solving the above technical problems, the present invention provides the following technical solutions:
一种N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备方法,在有机溶剂中,氧气条件下,以苯硼酸、硒粉、吗啡啉和N-取代马来酰亚胺为反应原料,在过渡金属铜催化剂、银盐、配体和碱的共同协同催化作用下,通过四组分串联反应得到N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物;A kind of preparation method of N-substituted-3-morpholinyl-4-phenylselenoyl maleimide compound, in organic solvent, under oxygen condition, with phenylboronic acid, selenium powder, morpholine and N-substituted N-substituted-3-morpholinyl-4-phenylselenyl group was obtained through a four-component series reaction under the synergistic catalysis of transition metal copper catalyst, silver salt, ligand and base using leimide as the raw material. Maleimide compounds;
上述的反应过程,可用下述的反应式表示:The above-mentioned reaction process can be represented by the following reaction formula:
所述苯硼酸、硒粉、吗啡啉和N-取代马来酰亚胺的摩尔比为3∶3∶3∶1。The molar ratio of phenylboronic acid, selenium powder, morpholine and N-substituted maleimide is 3:3:3:1.
(1)过渡金属铜催化剂(1) transition metal copper catalyst
本发明中的过渡金属铜催化剂是醋酸铜、溴化亚铜、三氟甲磺酸铜、氯化亚铜、溴化铜或碘化亚铜,优选为碘化亚铜,以摩尔量计,所述碘化亚铜的用量与所述N-取代马来酰亚胺用量的20%。The transition metal copper catalyst in the present invention is copper acetate, cuprous bromide, copper triflate, cuprous chloride, cupric bromide or cuprous iodide, preferably cuprous iodide, in molar terms, The amount of the cuprous iodide is 20% of the amount of the N-substituted maleimide.
(2)银盐(2) Silver salt
本发明中的银盐为氧化银、碳酸银、醋酸银或硝酸银,优选为碳酸银,以摩尔量计,所述银盐的用量与所述N-取代马来酰亚胺用量比为2∶1。The silver salt in the present invention is silver oxide, silver carbonate, silver acetate or silver nitrate, preferably silver carbonate, on a molar basis, the consumption ratio of the silver salt to the N-substituted maleimide consumption is 2 : 1.
(3)配体(3) Ligand
本发明中的配体为三苯基膦、三环己基膦、1,10-邻菲罗啉或2,2′-联吡啶,优选为1,10-邻菲罗啉。以摩尔量计,所述配体的用量为所述N-取代马来酰亚胺用量的20%。The ligand in the present invention is triphenylphosphine, tricyclohexylphosphine, 1,10-o-phenanthroline or 2,2'-bipyridine, preferably 1,10-o-phenanthroline. On a molar basis, the amount of the ligand is 20% of the amount of the N-substituted maleimide.
(4)碱(4) Alkali
本发明中的碱为碳酸铯、碳酸钾、碳酸钠、磷酸钾或磷酸钠中的至少一种,优选碳酸铯,以摩尔量计,所述碳酸铯的用量与所述N-取代马来酰亚胺用量比为3∶1。The alkali in the present invention is at least one of cesium carbonate, potassium carbonate, sodium carbonate, potassium phosphate or sodium phosphate, preferably cesium carbonate, in molar terms, the consumption of the cesium carbonate and the N-substituted maleyl The imine dosage ratio was 3:1.
(5)有机溶剂(5) Organic solvent
本发明中的反应溶剂为有机溶剂,所述有机溶剂为二甲基亚砜、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、1,4-二氧六烷、1,2-二氯乙烷、乙腈、甲苯、四氢呋喃中的至少一种,优选N,N-二甲基甲酰胺。The reaction solvent in the present invention is an organic solvent, and the organic solvent is dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, 1,4 -At least one of dioxane, 1,2-dichloroethane, acetonitrile, toluene, and tetrahydrofuran, preferably N,N-dimethylformamide.
(6)反应温度(6) Reaction temperature
本发明的制备方法中,反应温度为120-140℃,非限定性地例如可为120℃、130℃和140℃,反应温度优选140℃。In the preparation method of the present invention, the reaction temperature is 120-140°C, such as 120°C, 130°C and 140°C without limitation, and the reaction temperature is preferably 140°C.
(7)反应时间(7) Response time
在本发明的制备方法中,反应时间并无特别的限定,例如可通过液相色谱仪检测目标产物或原料的残留百分比而确定合适的反应时间,其通常为30-36小时,非限定性例如为30小时、32小时、34小时或36小时,反应时间优选36小时。In the preparation method of the present invention, the reaction time is not particularly limited. For example, a suitable reaction time can be determined by detecting the residual percentage of the target product or raw material by liquid chromatography, which is usually 30-36 hours. 30 hours, 32 hours, 34 hours or 36 hours, the reaction time is preferably 36 hours.
(8)分离纯化(8) Separation and purification
在一种优选的实施方式中,反应结束后的后处理步骤可为如下方法:反应结束后,将反应液冷却后加入水和乙酸乙酯萃取,将有机相用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,将浓缩物通过柱色谱分离,以石油醚和乙酸乙酯混合液为洗脱剂,收集洗脱液,浓缩后得到目标产物。In a preferred embodiment, the post-processing step after the reaction is completed can be the following method: after the reaction is completed, the reaction solution is cooled and then added with water and ethyl acetate for extraction, the organic phase is dried with anhydrous sodium sulfate, and filtered to chicken heart bottle, then spin off the solvent, separate the concentrate by column chromatography, use the mixture of petroleum ether and ethyl acetate as the eluent, collect the eluent, and concentrate to obtain the target product.
本发明提供的N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备方法具有如下有益效果:The preparation method of the N-substituted-3-morpholinyl-4-phenylselenoyl maleimide compound provided by the present invention has the following beneficial effects:
a)反应高效率、高收率、后处理简便;a) high reaction efficiency, high yield and easy post-processing;
b)利用廉价易得的硒粉作为硒基化试剂;b) using cheap and readily available selenium powder as a selenoylation reagent;
c)利用廉价易的铜作为催化剂;c) Utilize cheap and easy copper as a catalyst;
本发明以苯硼酸、硒粉、吗啡啉和N-取代马来酰亚胺为反应原料,在过渡金属铜催化剂、银盐、配体和碱的共同协同催化作用下,通过四组分串联反应得到N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物。本发明反应原料廉价易得、产物的产率和纯度高,为N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备开拓了合成路线和方法,为双取代马来酰亚胺衍生物的分子设计与合成提供新思路,具有重要的社会意义和经济意义。In the invention, phenylboronic acid, selenium powder, morpholine and N-substituted maleimide are used as reaction raw materials, and under the joint catalysis of transition metal copper catalyst, silver salt, ligand and base, a series reaction of four components is carried out. The N-substituted-3-morpholinyl-4-phenylselenomaleimide compound was obtained. The reaction raw materials of the invention are cheap and easy to obtain, the yield and purity of the products are high, the synthesis route and method are opened up for the preparation of N-substituted-3-morpholinyl-4-phenylselenoyl maleimide compounds, and the double-substituted The molecular design and synthesis of maleimide derivatives provide new ideas and have important social and economic significance.
具体实施方式Detailed ways
下面通过具体的实施例对本发明进行详细说明,但这些例举性实施方式的用途和目的仅用来例举本发明,并非对本发明的实际保护范围构成任何形式的任何限定,更非将本发明的保护范围局限于此。The present invention will be described in detail below through specific examples, but the purposes and purposes of these exemplary embodiments are only used to illustrate the present invention, and do not constitute any limitation to the actual protection scope of the present invention, nor do they limit the present invention. The scope of protection is limited to this.
以下实施例所给出的新化合物的数据和纯度均通过核磁共振鉴定。The data and purity of the novel compounds given in the following examples were identified by nuclear magnetic resonance.
实施1:Implementation 1:
N-环己基-3-吗啉基-4-苯硒基马来酰亚胺化合物的合成Synthesis of N-cyclohexyl-3-morpholinyl-4-phenylselenomaleimide compounds
在室温下,将苯硼酸(0.6mmol,3.0equiv)、硒粉(0.6mmol,3.0equiv)、吗啉(0.6mmol,3.0equiv)、N-环己基马来酰亚胺(0.2mmol,1.0equiv)、碘化亚铜(0.04mmol,0.2equiv)、1,10-邻菲罗啉(0.04mmol,0.2equiv)、碳酸银(0.4mmol,2.0equiv)、碳酸铯(0.6mmol,3.0equiv)、和2mL N,N-二甲基甲酰胺加入到反应管中,然后充入氧气,并且置换三次,在140℃反应温度下搅36h。将反应混合物冷却,然后加入乙酸乙酯进行稀释,用食盐水萃取,分离出有机相,用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,经柱层析分离得到产物(洗脱剂:石油醚∶乙酸乙酯为9∶1),产物为黄色液体,收率80%,产物重量为67mg。At room temperature, phenylboronic acid (0.6 mmol, 3.0 equiv), selenium powder (0.6 mmol, 3.0 equiv), morpholine (0.6 mmol, 3.0 equiv), N-cyclohexylmaleimide (0.2 mmol, 1.0 equiv) were combined ), cuprous iodide (0.04mmol, 0.2equiv), 1,10-o-phenanthroline (0.04mmol, 0.2equiv), silver carbonate (0.4mmol, 2.0equiv), cesium carbonate (0.6mmol, 3.0equiv), and 2 mL of N,N-dimethylformamide were added to the reaction tube, then filled with oxygen, and replaced three times, and stirred at a reaction temperature of 140° C. for 36 h. The reaction mixture was cooled, then diluted with ethyl acetate, extracted with brine, the organic phase was separated, dried with anhydrous sodium sulfate, filtered into a chicken heart flask, then the solvent was spun off, and the product was isolated by column chromatography (eluting). agent: petroleum ether:ethyl acetate 9:1), the product is a yellow liquid, the yield is 80%, and the weight of the product is 67 mg.
所得产物的核磁共振氢谱的数据如下:The data of the H NMR spectrum of the obtained product are as follows:
1H NMR(500MHz,CDCl3):δ7.30-7.28(m,2H),7.26-7.23(m,2H),7.19(t,J=7.0Hz,1H),4.11(t,J=4.70Hz,4H),3.96(tt,J=8.3,3.4Hz,1H),3.66(t,J=4.70Hz,4H),2.10-2.03(m,2H),1.82(d,J=3.1Hz,2H),1.68-1.66(m,2H),1.34-1.18(m,4H); 1 H NMR (500 MHz, CDCl 3 ): δ 7.30-7.28 (m, 2H), 7.26-7.23 (m, 2H), 7.19 (t, J=7.0 Hz, 1H), 4.11 (t, J=4.70 Hz) , 4H), 3.96 (tt, J=8.3, 3.4Hz, 1H), 3.66 (t, J=4.70Hz, 4H), 2.10-2.03 (m, 2H), 1.82 (d, J=3.1Hz, 2H) , 1.68-1.66 (m, 2H), 1.34-1.18 (m, 4H);
所得产物的核磁共振碳谱的数据如下:The data of the carbon nuclear magnetic resonance spectrum of the obtained product are as follows:
13C NMR(125MHz,CDCl3):δ170.2,166.4,149.5,132.4,129.4,129.3,126.6,87.6,66.9,51.4,48.4,29.9,26.0,25.2; 13 C NMR (125 MHz, CDCl 3 ): δ 170.2, 166.4, 149.5, 132.4, 129.4, 129.3, 126.6, 87.6, 66.9, 51.4, 48.4, 29.9, 26.0, 25.2;
所得产物的高分辨质谱数据如下:The high-resolution mass spectrometry data of the obtained product are as follows:
HRMS(ESI):calcd for C20H24N2O3Se[M+Na]+443.0850,found 443.0864.HRMS(ESI): calcd for C 20 H 24 N 2 O 3 Se[M+Na] + 443.0850, found 443.0864.
实施2:Implementation 2:
N-苄基-3-吗啉基-4-苯硒基马来酰亚胺化合物的合成Synthesis of N-benzyl-3-morpholinyl-4-phenylselenomaleimide compounds
在室温下,将苯硼酸(0.6mmol,3.0equiv)、硒粉(0.6mmol,3.0equiv)、吗啉(0.6mmol,3.0equiv)、N-苄基马来酰亚胺(0.2mmol,1.0equiv)、碘化亚铜(0.04mmol,0.2equiv)、1,10-邻菲罗啉(0.04mmol,0.2equiv)、碳酸银(0.4mmol,2.0equiv)、碳酸铯(0.6mmol,3.0equiv)、和2mL N,N-二甲基甲酰胺加入到反应管中,然后充入氧气,并且置换三次,在140℃反应温度下搅36h。将反应混合物冷却,然后加入乙酸乙酯进行稀释,用食盐水萃取,分离出有机相,用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,经柱层析分离得到产物(洗脱剂:石油醚∶乙酸乙酯为9∶1),产物为黄色液体,收率79%,产物重量为67mg。At room temperature, phenylboronic acid (0.6 mmol, 3.0 equiv), selenium powder (0.6 mmol, 3.0 equiv), morpholine (0.6 mmol, 3.0 equiv), N-benzylmaleimide (0.2 mmol, 1.0 equiv) were combined ), cuprous iodide (0.04mmol, 0.2equiv), 1,10-o-phenanthroline (0.04mmol, 0.2equiv), silver carbonate (0.4mmol, 2.0equiv), cesium carbonate (0.6mmol, 3.0equiv), and 2 mL of N,N-dimethylformamide were added to the reaction tube, then filled with oxygen, and replaced three times, and stirred at a reaction temperature of 140° C. for 36 h. The reaction mixture was cooled, then diluted with ethyl acetate, extracted with brine, the organic phase was separated, dried with anhydrous sodium sulfate, filtered into a chicken heart flask, then the solvent was spun off, and the product was isolated by column chromatography (eluting). agent: petroleum ether:ethyl acetate 9:1), the product is a yellow liquid, the yield is 79%, and the weight of the product is 67 mg.
所得产物的核磁共振氢谱的数据如下:The data of the H NMR spectrum of the obtained product are as follows:
1H NMR(500MHz,CDCl3):δ7.41-7.39(m,2H),7.36-7.22(m,8H),4.72(s,2H),4.16(t,J=4.70Hz,4H),3.66(t,J=4.70Hz,4H); 1 H NMR (500 MHz, CDCl 3 ): δ 7.41-7.39 (m, 2H), 7.36-7.22 (m, 8H), 4.72 (s, 2H), 4.16 (t, J=4.70 Hz, 4H), 3.66 (t, J=4.70Hz, 4H);
所得产物的核磁共振碳谱的数据如下:The data of the carbon nuclear magnetic resonance spectrum of the obtained product are as follows:
13C NMR(125MHz,CDCl3):δ170.0,166.3,149.7,136.5,132.3,129.5,129.4,128.6,128.6,127.7,126.7,87.2,66.9,48.5,42.1; 13 C NMR (125 MHz, CDCl 3 ): δ 170.0, 166.3, 149.7, 136.5, 132.3, 129.5, 129.4, 128.6, 128.6, 127.7, 126.7, 87.2, 66.9, 48.5, 42.1;
所得产物的高分辨质谱数据如下:The high-resolution mass spectrometry data of the obtained product are as follows:
HRMS(ESI):calcd for C21H20N2O3Se[M+H]+429.0718,found 429.0726.HRMS(ESI): calcd for C 21 H 20 N 2 O 3 Se[M+H] + 429.0718, found 429.0726.
实施3:Implementation 3:
N-(4-甲基苄基)-3-吗啉基-4-苯硒基马来酰亚胺化合物的合成Synthesis of N-(4-methylbenzyl)-3-morpholinyl-4-phenylselenomaleimide compounds
在室温下,将苯硼酸(0.6mmol,3.0equiv)、硒粉(0.6mmol,3.0equiv)、吗啉(0.6mmol,3.0equiv)、N-(4-甲基苄基)马来酰亚胺(0.2mmol,1.0equiv)、碘化亚铜(0.04mmol,0.2equiv)、1,10-邻菲罗啉(0.04mmol,0.2equiv)、碳酸银(0.4mmol,2.0equiv)、碳酸铯(0.6mmol,3.0equiv)、和2mL N,N-二甲基甲酰胺加入到反应管中,然后充入氧气,并且置换三次,在140℃反应温度下搅36h。将反应混合物冷却,然后加入乙酸乙酯进行稀释,用食盐水萃取,分离出有机相,用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,经柱层析分离得到产物(洗脱剂:石油醚∶乙酸乙酯为9∶1),产物为黄色固体,熔点为116-117℃,收率77%,产物重量为68mg。At room temperature, phenylboronic acid (0.6 mmol, 3.0 equiv), selenium powder (0.6 mmol, 3.0 equiv), morpholine (0.6 mmol, 3.0 equiv), N-(4-methylbenzyl)maleimide (0.2mmol, 1.0equiv), cuprous iodide (0.04mmol, 0.2equiv), 1,10-phenanthroline (0.04mmol, 0.2equiv), silver carbonate (0.4mmol, 2.0equiv), cesium carbonate (0.6 mmol, 3.0 equiv), and 2 mL of N,N-dimethylformamide were added to the reaction tube, then filled with oxygen, and replaced three times, and stirred at a reaction temperature of 140° C. for 36 h. The reaction mixture was cooled, then diluted with ethyl acetate, extracted with brine, the organic phase was separated, dried with anhydrous sodium sulfate, filtered into a chicken heart flask, then the solvent was spun off, and the product was isolated by column chromatography (eluting). agent: petroleum ether:ethyl acetate: 9:1), the product is a yellow solid, the melting point is 116-117°C, the yield is 77%, and the weight of the product is 68 mg.
所得产物的核磁共振氢谱的数据如下:The data of the H NMR spectrum of the obtained product are as follows:
1H NMR(500MHz,CDCl3):δ7.29-7.19(m,7H),7.12-7.11(m,2H),4.65(s,2H),4.12(t,J=4.70Hz,4H),3.61(t,J=4.70Hz,4H),2.32(s,3H); 1 H NMR (500 MHz, CDCl 3 ): δ 7.29-7.19 (m, 7H), 7.12-7.11 (m, 2H), 4.65 (s, 2H), 4.12 (t, J=4.70 Hz, 4H), 3.61 (t, J=4.70Hz, 4H), 2.32(s, 3H);
所得产物的核磁共振碳谱的数据如下:The data of the carbon nuclear magnetic resonance spectrum of the obtained product are as follows:
13C NMR(125MHz,CDCl3):δ170.0,166.2,149.7,137.5,133.6,132.3,129.4,129.3,128.7,126.7,87.2,66.9,48.4,41.8,21.1; 13 C NMR (125 MHz, CDCl 3 ): δ 170.0, 166.2, 149.7, 137.5, 133.6, 132.3, 129.4, 129.3, 128.7, 126.7, 87.2, 66.9, 48.4, 41.8, 21.1;
所得产物的高分辨质谱数据如下:The high-resolution mass spectrometry data of the obtained product are as follows:
HRMS(ESI):calcd for C22H22N2O3Se[M+H]+443.0875,found 443.0883.HRMS(ESI): calcd for C 22 H 22 N 2 O 3 Se[M+H] + 443.0875, found 443.0883.
实施4:Implementation 4:
N-(4-甲氧基苄基)-3-吗啉基-4-苯硒基马来酰亚胺化合物的合成Synthesis of N-(4-Methoxybenzyl)-3-morpholinyl-4-phenylselenomaleimide Compounds
在室温下,将苯硼酸(0.6mmol,3.0equiv)、硒粉(0.6mmol,3.0equiv)、吗啉(0.6mmol,3.0equiv)、N-(4-甲氧基苄基)马来酰亚胺(0.2mmol,1.0equiv)、碘化亚铜(0.04mmol,0.2equiv)、1,10-邻菲罗啉(0.04mmol,0.2equiv)、碳酸银(0.4mmol,2.0equiv)、碳酸铯(0.6mmol,3.0equiv)、和2mL N,N-二甲基甲酰胺加入到反应管中,然后充入氧气,并且置换三次,在140℃反应温度下搅36h。将反应混合物冷却,然后加入乙酸乙酯进行稀释,用食盐水萃取,分离出有机相,用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,经柱层析分离得到产物(洗脱剂:石油醚∶乙酸乙酯为9∶1),产物为黄色液体,收率88%,产物重量为80mg。At room temperature, phenylboronic acid (0.6 mmol, 3.0 equiv), selenium powder (0.6 mmol, 3.0 equiv), morpholine (0.6 mmol, 3.0 equiv), N-(4-methoxybenzyl)maleimide Amine (0.2mmol, 1.0equiv), cuprous iodide (0.04mmol, 0.2equiv), 1,10-phenanthroline (0.04mmol, 0.2equiv), silver carbonate (0.4mmol, 2.0equiv), cesium carbonate ( 0.6 mmol, 3.0 equiv), and 2 mL of N,N-dimethylformamide were added to the reaction tube, then filled with oxygen, and replaced three times, and stirred at a reaction temperature of 140° C. for 36 h. The reaction mixture was cooled, then diluted with ethyl acetate, extracted with brine, the organic phase was separated, dried with anhydrous sodium sulfate, filtered into a chicken heart flask, then the solvent was spun off, and the product was isolated by column chromatography (eluting). agent: petroleum ether: ethyl acetate 9: 1), the product is a yellow liquid, the yield is 88%, and the weight of the product is 80 mg.
所得产物的核磁共振氢谱的数据如下:The data of the H NMR spectrum of the obtained product are as follows:
1H NMR(500MHz,CDCl3):δ7.36-7.20(m,7H),6.86-6.85(m,2H),4.65(s,2H),4.14(t,J=4.70Hz,4H),3.80(s,3H),3.64(t,J=4.70Hz,4H); 1 H NMR (500 MHz, CDCl 3 ): δ 7.36-7.20 (m, 7H), 6.86-6.85 (m, 2H), 4.65 (s, 2H), 4.14 (t, J=4.70 Hz, 4H), 3.80 (s, 3H), 3.64 (t, J=4.70Hz, 4H);
所得产物的核磁共振碳谱的数据如下:The data of the carbon nuclear magnetic resonance spectrum of the obtained product are as follows:
13C NMR(125MHz,CDCl3):δ170.1,166.3,159.2,149.7,132.3,130.2,129.4,129.4,128.8,126.7,114.0,87.1,66.9,55.3,48.4,41.5; 13 C NMR (125 MHz, CDCl 3 ): δ 170.1, 166.3, 159.2, 149.7, 132.3, 130.2, 129.4, 129.4, 128.8, 126.7, 114.0, 87.1, 66.9, 55.3, 48.4, 41.5;
所得产物的高分辨质谱数据如下:The high-resolution mass spectrometry data of the obtained product are as follows:
HRMS(ESI):calcd for C22H22N2O4Se[M+H]+459.0824,found 459.0832.HRMS(ESI): calcd for C 22 H 22 N 2 O 4 Se[M+H] + 459.0824, found 459.0832.
实施5:Implementation 5:
N-(4-氟苄基)-3-吗啉基-4-苯硒基马来酰亚胺化合物的合成Synthesis of N-(4-Fluorobenzyl)-3-morpholinyl-4-phenylselenomaleimide Compounds
在室温下,将苯硼酸(0.6mmol,3.0equiv)、硒粉(0.6mmol,3.0equiv)、吗啉(0.6mmol,3.0equiv)、N-(4-氟苄基)马来酰亚胺(0.2mmol,1.0equiv)、碘化亚铜(0.04mmol,0.2equiv)、1,10-邻菲罗啉(0.04mmol,0.2equiv)、碳酸银(0.4mmol,2.0equiv)、碳酸铯(0.6mmol,3.0equiv)、和2mL N,N-二甲基甲酰胺加入到反应管中,然后充入氧气,并且置换三次,在140℃反应温度下搅36h。将反应混合物冷却,然后加入乙酸乙酯进行稀释,用食盐水萃取,分离出有机相,用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,经柱层析分离得到产物(洗脱剂:石油醚∶乙酸乙酯为9∶1),产物为黄色液体,收率65%,产物重量为60mg。At room temperature, phenylboronic acid (0.6 mmol, 3.0 equiv), selenium powder (0.6 mmol, 3.0 equiv), morpholine (0.6 mmol, 3.0 equiv), N-(4-fluorobenzyl)maleimide ( 0.2mmol, 1.0equiv), cuprous iodide (0.04mmol, 0.2equiv), 1,10-o-phenanthroline (0.04mmol, 0.2equiv), silver carbonate (0.4mmol, 2.0equiv), cesium carbonate (0.6mmol) , 3.0 equiv), and 2 mL of N,N-dimethylformamide were added to the reaction tube, then filled with oxygen, and replaced three times, and stirred at a reaction temperature of 140° C. for 36 h. The reaction mixture was cooled, then diluted with ethyl acetate, extracted with brine, the organic phase was separated, dried with anhydrous sodium sulfate, filtered into a chicken heart flask, then the solvent was spun off, and the product was isolated by column chromatography (eluting). agent: petroleum ether:ethyl acetate 9:1), the product is a yellow liquid, the yield is 65%, and the weight of the product is 60 mg.
所得产物的核磁共振氢谱的数据如下:The data of the H NMR spectrum of the obtained product are as follows:
1H NMR(500MHz,CDCl3):δ7.39-7.37(m,2H),7.32-7.30(m,2H),7.28-7.21(m,4H),7.02(t,J=8.6Hz,2H),4.68(s,2H),4.16(t,J=4.70Hz,4H),3.66(t,J=4.70Hz,4H); 1 H NMR (500 MHz, CDCl 3 ): δ 7.39-7.37 (m, 2H), 7.32-7.30 (m, 2H), 7.28-7.21 (m, 4H), 7.02 (t, J=8.6 Hz, 2H) , 4.68(s, 2H), 4.16(t, J=4.70Hz, 4H), 3.66(t, J=4.70Hz, 4H);
所得产物的核磁共振碳谱的数据如下:The data of the carbon nuclear magnetic resonance spectrum of the obtained product are as follows:
13C NMR(125MHz,CDCl3):δ169.9,166.2,162.4(d,JF=246.5Hz),149.7,136.0,132.3(d,JF=3.2Hz),132.2,130.5(d,JF=8.1Hz),129.4(d,JF=9.3Hz),126.7,115.4(d,JF=21.6Hz),87.2,66.9,48.5,41.3; 13 C NMR (125 MHz, CDCl 3 ): δ 169.9, 166.2, 162.4 (d, J F = 246.5 Hz), 149.7, 136.0, 132.3 (d, J F = 3.2 Hz), 132.2, 130.5 (d, J F = 3.2 Hz) = 8.1 Hz), 129.4 (d, J F =9.3 Hz), 126.7, 115.4 (d, J F =21.6 Hz), 87.2, 66.9, 48.5, 41.3;
所得产物的核磁共振氟谱的数据如下:The data of the fluorine nuclear magnetic resonance spectrum of the obtained product are as follows:
19F NMR(470MHz,CDCl3):δ-62.7(s,1F); 19 F NMR (470 MHz, CDCl 3 ): δ-62.7 (s, 1F);
所得产物的高分辨质谱数据如下:The high-resolution mass spectrometry data of the obtained product are as follows:
HRMS(ESI):calcd for C21H19FN2O3Se[M+H]+447.0624,found 447.0639.HRMS(ESI): calcd for C 21 H 19 FN 2 O 3 Se[M+H] + 447.0624, found 447.0639.
实施6:Implementation 6:
N-(4-三氟甲基苄基)-3-吗啉基-4-苯硒基马来酰亚胺化合物的合成Synthesis of N-(4-trifluoromethylbenzyl)-3-morpholinyl-4-phenylselenomaleimide compounds
在室温下,将苯硼酸(0.6mmol,3.0equiv)、硒粉(0.6mmol,3.0equiv)、吗啉(0.6mmol,3.0equiv)、N-(4-三氟甲基苄基)马来酰亚胺(0.2mmol,1.0equiv)、碘化亚铜(0.04mmol,0.2equiv)、1,10-邻菲罗啉(0.04mmol,0.2equiv)、碳酸银(0.4mmol,2.0equiv)、碳酸铯(0.6mmol,3.0equiv)、和2mL N,N-二甲基甲酰胺加入到反应管中,然后充入氧气,并且置换三次,在140℃反应温度下搅36h。将反应混合物冷却,然后加入乙酸乙酯进行稀释,用食盐水萃取,分离出有机相,用无水硫酸钠干燥,过滤至鸡心瓶,然后旋掉溶剂,经柱层析分离得到产物(洗脱剂:石油醚∶乙酸乙酯为9∶1),产物为黄色液体,收率49%,产物重量为49mg。At room temperature, phenylboronic acid (0.6 mmol, 3.0 equiv), selenium powder (0.6 mmol, 3.0 equiv), morpholine (0.6 mmol, 3.0 equiv), N-(4-trifluoromethylbenzyl)maleyl Imine (0.2mmol, 1.0equiv), cuprous iodide (0.04mmol, 0.2equiv), 1,10-phenanthroline (0.04mmol, 0.2equiv), silver carbonate (0.4mmol, 2.0equiv), cesium carbonate (0.6 mmol, 3.0 equiv), and 2 mL of N,N-dimethylformamide were added to the reaction tube, then filled with oxygen, and replaced three times, and stirred at a reaction temperature of 140° C. for 36 h. The reaction mixture was cooled, then diluted with ethyl acetate, extracted with brine, the organic phase was separated, dried with anhydrous sodium sulfate, filtered into a chicken heart flask, then the solvent was spun off, and the product was isolated by column chromatography (eluting). agent: petroleum ether: ethyl acetate is 9: 1), the product is a yellow liquid, the yield is 49%, and the weight of the product is 49 mg.
所得产物的核磁共振氢谱的数据如下:The data of the H NMR spectrum of the obtained product are as follows:
1H NMR(500MHz,CDCl3):δ7.57(d,J=8.0Hz,2H),7.48(d,J=8.0Hz,2H),7.30-7.29(m,2H),7.26-7.19(m,3H),4.74(s,2H),4.14(t,J=4.70Hz,4H),3.64(t,J=4.70Hz,4H); 1 H NMR (500 MHz, CDCl 3 ): δ 7.57 (d, J=8.0 Hz, 2H), 7.48 (d, J=8.0 Hz, 2H), 7.30-7.29 (m, 2H), 7.26-7.19 (m , 3H), 4.74 (s, 2H), 4.14 (t, J=4.70Hz, 4H), 3.64 (t, J=4.70Hz, 4H);
所得产物的核磁共振碳谱的数据如下:The data of the carbon nuclear magnetic resonance spectrum of the obtained product are as follows:
13C NMR(125MHz,CDCl3):δ169.8,166.2,149.6,140.3,132.1,130.0(q,JF=32.4Hz),129.5,129.4,128.9,126.8,126.7,126.2(q,JF=272.3Hz),125.6(q,JF=3.5Hz),87.2,66.9,48.5,41.6; 13 C NMR (125 MHz, CDCl 3 ): δ 169.8, 166.2, 149.6, 140.3, 132.1, 130.0 (q, J F = 32.4 Hz), 129.5, 129.4, 128.9, 126.8, 126.7, 126.2 (q, J F = 32.4 Hz) 272.3 Hz), 125.6 (q, J F =3.5 Hz), 87.2, 66.9, 48.5, 41.6;
所得产物的核磁共振氟谱的数据如下:The data of the fluorine nuclear magnetic resonance spectrum of the obtained product are as follows:
19F NMR(470MHz,CDCl3):δ-62.6(s,3F); 19 F NMR (470 MHz, CDCl 3 ): δ-62.6 (s, 3F);
所得产物的高分辨质谱数据如下:The high-resolution mass spectrometry data of the obtained product are as follows:
HRMS(ESI):calcd for C22H19F3N2O3Se[M+H]+497.0592,found 497.0584.HRMS(ESI): calcd for C 22 H 19 F 3 N 2 O 3 Se[M+H] + 497.0592, found 497.0584.
由上述1-6实施例可看出,当采用本发明的所述方法时,能够以高产率、高纯度得到N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物。It can be seen from the above examples 1-6 that when the method of the present invention is adopted, the N-substituted-3-morpholinyl-4-phenylselenylmaleimide compound can be obtained with high yield and high purity .
实施例7-11Examples 7-11
除将其中的过渡金属催化剂碘化亚铜分别替换为如下的铜盐外,与实施例1相同的方式而分别实施了实施例7-11,所使用铜盐化合物和相应产物的收率如下表1所示。Except for replacing the transition metal catalyst cuprous iodide with the following copper salts, respectively, Examples 7-11 were implemented in the same manner as Example 1, and the yields of the copper salt compounds and corresponding products used were as follows: 1 shown.
表1Table 1
由上表1可看出,当使用其它铜盐时,均没有任何目标产物,由此证明了碘化亚铜是该反应成功的关键因素,且对该反应体系最为有效。As can be seen from Table 1 above, when other copper salts are used, there is no target product, which proves that cuprous iodide is the key factor for the success of the reaction, and the reaction system is the most effective.
实施例12-14Examples 12-14
除将其中的1,10-邻菲罗啉配体分别替换为如下的配体外,与实施例1相同的方式而分别实施了实施例12-14,所使用配体和相应产物的收率如下表2所示。Except for replacing the 1,10-phenanthroline ligands with the following ligands, the same way as in Example 1 was carried out, and the yields of the ligands used and the corresponding products were respectively implemented in Examples 12-14. As shown in Table 2 below.
表2Table 2
由上表2可看出,当使用三苯基膦或者三环己基膦时,反应不能够发生,利用2,2′-联吡啶作为配体时,产率受到一定的影响,由此证明了1,10-邻菲罗啉是该反应成功的关键因素,且对该反应体系最为有效。It can be seen from Table 2 above that when triphenylphosphine or tricyclohexylphosphine is used, the reaction cannot occur, and when 2,2'-bipyridine is used as a ligand, the yield is affected to a certain extent, which proves that 1,10-phenanthroline is the key factor for the success of this reaction, and it is the most effective for this reaction system.
实施例15-17Examples 15-17
除将其中的碳酸银分别替换为如下的银盐外,与实施例1相同的方式而分别实施了实施例15-17,所使用银盐和相应产物的收率如下表3所示。Examples 15-17 were implemented in the same manner as in Example 1, except that the silver carbonate was replaced with the following silver salts, respectively. The yields of the silver salts used and the corresponding products are shown in Table 3 below.
表3table 3
由上表3可看出,当使用其他银盐时,反应均不能发生,由此证明了碳酸银的使用是该反应成功的关键因素,且对该反应体系最为有效。As can be seen from the above table 3, when other silver salts are used, the reaction cannot occur, thus proving that the use of silver carbonate is the key factor for the success of the reaction, and the reaction system is the most effective.
实施例18-21Examples 18-21
除将其中的碳酸铯分别替换为如下的无机碱外,与实施例1相同的方式而分别实施了实施例18-21,所使用碱和相应产物的收率如下表4所示。Examples 18-21 were carried out in the same manner as in Example 1, except that the cesium carbonate was replaced with the following inorganic bases, respectively. The bases used and the yields of the corresponding products are shown in Table 4 below.
表4Table 4
由上表4可看出,当使用其他无机碱时,没有任何产物,由此证明了碳酸铯的使用是该反应成功的关键因素,且对该反应体系最为有效。As can be seen from Table 4 above, when other inorganic bases are used, there is no product, which proves that the use of cesium carbonate is the key factor for the success of the reaction, and the reaction system is the most effective.
实施例22-29Examples 22-29
除将其中的有机溶剂N,N-二甲基甲酰胺分别替换为如下的有机溶剂外,以与实施例1相同的方式而分别实施了实施22-29,所使用有机溶剂和相应产物的收率如下表5所示。Except that the organic solvent N,N-dimethylformamide therein was replaced with the following organic solvents, respectively, implementations 22-29 were carried out in the same manner as in Example 1, and the organic solvents used and the corresponding products were recovered. The rates are shown in Table 5 below.
表5table 5
由上表5可看出,使用其他强极性溶剂如二甲亚砜和N,N-二甲基乙酰胺,非极性溶剂甲苯,以及弱配位溶剂乙腈和四氢呋喃均没有任何产物,证明了有机溶剂的合适选择对反应能否进行有着显著的,甚至是决定性的影响。As can be seen from Table 5 above, other strong polar solvents such as dimethyl sulfoxide and N,N-dimethylacetamide, non-polar solvents toluene, and weakly coordinating solvents acetonitrile and tetrahydrofuran did not have any products, which proved that The appropriate choice of organic solvent has a significant or even decisive influence on whether the reaction can be carried out.
综上所述,由上述所有实施例可明确看出,当采用本发明的方法使用过渡金属催化剂(尤其是碘化亚铜)、配体(尤其是1,10-邻菲罗啉)、银盐(尤其是碳酸银)、无机碱(尤其是碳酸铯)和合适的有机溶剂(尤其是N,N-二甲基甲酰胺)所组成的催化反应体系时,使得苯硼酸、硒粉、吗啡啉和N-取代马来酰亚胺化合物在氧气条件下,通过铜催化的四组分串联反应以高产率和高纯度合成得到N-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物,为该类化合物的高效快捷合成提供了全新的合成路线。To sum up, it can be clearly seen from all the above examples that when the method of the present invention uses a transition metal catalyst (especially cuprous iodide), a ligand (especially 1,10-o-phenanthroline), silver In the catalytic reaction system composed of salt (especially silver carbonate), inorganic base (especially cesium carbonate) and suitable organic solvent (especially N,N-dimethylformamide), phenylboronic acid, selenium powder, morphine N-substituted-3-morpholinyl-4-phenylselenylmaleimide was synthesized in high yield and purity by copper-catalyzed four-component tandem reaction of morpholino and N-substituted maleimide compounds under oxygen conditions The imide compound provides a new synthetic route for the efficient and fast synthesis of this type of compound.
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然科研对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, but not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that: It is still scientific research to modify the technical solutions recorded in the foregoing embodiments, or to make equivalent replacements for some or all of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the technical solutions of the embodiments of the present invention. scope.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010816745.0A CN111978236B (en) | 2020-08-12 | 2020-08-12 | A kind of preparation method of N-substituted-3-morpholinyl-4-phenylselenyl maleimide compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010816745.0A CN111978236B (en) | 2020-08-12 | 2020-08-12 | A kind of preparation method of N-substituted-3-morpholinyl-4-phenylselenyl maleimide compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111978236A true CN111978236A (en) | 2020-11-24 |
CN111978236B CN111978236B (en) | 2022-01-04 |
Family
ID=73435220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010816745.0A Active CN111978236B (en) | 2020-08-12 | 2020-08-12 | A kind of preparation method of N-substituted-3-morpholinyl-4-phenylselenyl maleimide compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111978236B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114031537A (en) * | 2021-09-18 | 2022-02-11 | 温州医科大学 | A kind of synthetic method of 3-deuterated methylthio-4-morpholinyl maleimide compound |
CN114031538A (en) * | 2021-09-18 | 2022-02-11 | 温州医科大学 | Preparation method of 3-deuterated methylseleno-4-morpholinyl maleimide compound |
CN115286555A (en) * | 2021-11-26 | 2022-11-04 | 温州医科大学 | Synthetic method of 3-alkynylselendole compound |
CN115286552A (en) * | 2021-12-30 | 2022-11-04 | 温州医科大学 | Preparation method of mono-seleno maleimide compound |
CN115353477A (en) * | 2022-01-19 | 2022-11-18 | 温州医科大学 | A kind of preparation method of bis-selenomaleimide compound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108863878A (en) * | 2018-02-19 | 2018-11-23 | 温州医科大学 | A kind of beta-hydroxy selenide compound and preparation method |
-
2020
- 2020-08-12 CN CN202010816745.0A patent/CN111978236B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108863878A (en) * | 2018-02-19 | 2018-11-23 | 温州医科大学 | A kind of beta-hydroxy selenide compound and preparation method |
Non-Patent Citations (4)
Title |
---|
TAO LENG,等: "Silver-Catalyzed One-Pot Three-Component Selective Synthesis of β-Hydroxy Selenides", 《ADV. SYNTH. CATAL.》 * |
XUE GAO,等: "Oxidative Aminoarylselenation of Maleimides via Copper-Catalyz Four-Component Cross-Coupling", 《ORG. LETT.》 * |
YAOKUN REN,等: "Synthesis of ArSe-Substituted Aniline Derivatives by C(sp2)-H Functionalization", 《ASIAN J. ORG. CHEM.》 * |
YE-FEI YANG,等: "Cu-Catalyzed Radical Selenylation of Olefin: A Direct Access to Vinyl Selenides", 《ADV. SYNTH. CATAL.》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114031537A (en) * | 2021-09-18 | 2022-02-11 | 温州医科大学 | A kind of synthetic method of 3-deuterated methylthio-4-morpholinyl maleimide compound |
CN114031538A (en) * | 2021-09-18 | 2022-02-11 | 温州医科大学 | Preparation method of 3-deuterated methylseleno-4-morpholinyl maleimide compound |
CN115286555A (en) * | 2021-11-26 | 2022-11-04 | 温州医科大学 | Synthetic method of 3-alkynylselendole compound |
CN115286552A (en) * | 2021-12-30 | 2022-11-04 | 温州医科大学 | Preparation method of mono-seleno maleimide compound |
CN115286552B (en) * | 2021-12-30 | 2023-10-20 | 温州医科大学 | Preparation method of monoseleno maleimide compound |
CN115353477A (en) * | 2022-01-19 | 2022-11-18 | 温州医科大学 | A kind of preparation method of bis-selenomaleimide compound |
CN115353477B (en) * | 2022-01-19 | 2023-10-20 | 温州医科大学 | A kind of preparation method of diselenomaleimide compounds |
Also Published As
Publication number | Publication date |
---|---|
CN111978236B (en) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111978236A (en) | Preparation method of N-substituted-3-morpholinyl-4-phenylseleno maleimide compound | |
CN109705013B (en) | A kind of 1-(4-methylbenzyl)-3-amino-4-methylselenomaleimide compound and preparation method thereof | |
CN101798279B (en) | Method for preparing iron-catalyzed pyrrole and pyrrole cyclic compounds | |
CN112028809A (en) | Preparation method of 3-amino-4-phenylseleno maleimide compound | |
CN107935812B (en) | Method for preparing polyaryl substituted naphthalene derivative by reaction of alkyl aryl ketone and tolane under catalysis of ruthenium | |
CN109651225B (en) | Preparation method of 1-methyl-3-morphinyl-4-arylmercapto maleimide compound | |
CN111333564B (en) | A kind of synthetic method of 3-alkylmercapto-1-methyl-4-morpholino maleimide compound | |
CN111848630A (en) | Method for preparing pyrrolo[1,2-a]indole compounds based on alkynyl-substituted aza-p-methylenebenzoquinone | |
CN108314658B (en) | A kind of preparation method of multi-substituted oxazole derivatives | |
CN111978237A (en) | Preparation method of 3-morpholinyl-4-arylseleno maleimide compound | |
CN112028808B (en) | Preparation method of N-substituted-3-methyl mercapto-4-morpholinyl maleimide compound | |
CN110357805B (en) | Preparation method of N-methyl-3-phenylseleno maleimide compound | |
CN106008402A (en) | Epsilon-trifluoromethyl substituted amide preparing method | |
CN112661690B (en) | Preparation method of 3-chloro-4-amino maleimide compound | |
CN103275027A (en) | Synthesis method of alpha-keto amide compound | |
CN112661689B (en) | A kind of preparation method of 3-bromo-4-amino maleimide compound | |
CN114874139B (en) | A kind of synthesis method of 1-benzyl or allyl 3,4-dihydroisoquinoline | |
CN106892826A (en) | A kind of preparation method and application of amine and imines N-methyl | |
CN106831474B (en) | One kind-the α containing alpha-aromatic, β-diamino acid ester derivant and its synthetic method and application | |
CN108558785A (en) | A kind of 5- aryl -2- arylseleno -1,3- oxazole compounds and preparation method | |
CN106008309A (en) | Method for preparing isatin derivative by visible-light photocatalysis | |
CN111925310A (en) | 3-amino-4-arylseleno maleimide compound and preparation method thereof | |
CN111978235B (en) | A kind of preparation method of 3-amino-4-methylmercaptomaleimide compound | |
CN112724063B (en) | Preparation method of 3-iodine-4-amido maleimide compound | |
CN108912045B (en) | A kind of 2-phenylselenoquinoline compound and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |